BidaskClub downgraded shares of Albireo Pharma (NASDAQ:ALBO) from a hold rating to a sell rating in a research note published on Thursday morning.
ALBO has been the topic of a number of other reports. Wedbush reiterated an outperform rating on shares of Albireo Pharma in a research note on Monday, July 16th. Zacks Investment Research upgraded Albireo Pharma from a hold rating to a buy rating and set a $36.00 target price on the stock in a research note on Tuesday, July 24th. Finally, Cowen reiterated a buy rating on shares of Albireo Pharma in a research note on Wednesday, August 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $59.40.
Shares of NASDAQ:ALBO opened at $30.32 on Thursday. Albireo Pharma has a 1-year low of $21.25 and a 1-year high of $39.87. The firm has a market cap of $394.53 million, a price-to-earnings ratio of -9.63 and a beta of 1.45.
In other Albireo Pharma news, insider Ronald Harold Wilfred Cooper bought 788 shares of the stock in a transaction dated Tuesday, August 14th. The shares were bought at an average cost of $31.85 per share, for a total transaction of $25,097.80. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 3.60% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALBO. BlackRock Inc. raised its stake in Albireo Pharma by 582.8% in the 2nd quarter. BlackRock Inc. now owns 524,276 shares of the biopharmaceutical company’s stock valued at $18,611,000 after acquiring an additional 447,496 shares during the period. Federated Investors Inc. PA raised its stake in Albireo Pharma by 89.1% in the 2nd quarter. Federated Investors Inc. PA now owns 586,146 shares of the biopharmaceutical company’s stock valued at $20,808,000 after acquiring an additional 276,221 shares during the period. Millennium Management LLC raised its stake in Albireo Pharma by 234.0% in the 1st quarter. Millennium Management LLC now owns 155,611 shares of the biopharmaceutical company’s stock valued at $5,068,000 after acquiring an additional 109,017 shares during the period. Northern Trust Corp raised its stake in Albireo Pharma by 533.1% in the 2nd quarter. Northern Trust Corp now owns 99,819 shares of the biopharmaceutical company’s stock valued at $3,544,000 after acquiring an additional 84,053 shares during the period. Finally, Chicago Capital LLC raised its stake in Albireo Pharma by 48.4% in the 2nd quarter. Chicago Capital LLC now owns 134,748 shares of the biopharmaceutical company’s stock valued at $4,784,000 after acquiring an additional 43,917 shares during the period. Institutional investors own 63.41% of the company’s stock.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Read More: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.